Dianthus Therapeutics Inc. (DNTH)
NASDAQ
Closed
Aug 24, 2026
Day's Range
105.0552 wk Range
22.81Overview - DNTH - Dianthus Therapeutics Inc.
Key Statistics
Valuation
Enterprise Value
5.32B
P/E (Trailing)
‪3.30‬
P/E (Forward)
‪-23.42‬
PEG Ratio
‪1.45‬
Price / Sales (TTM)
‪3,263.81‬
Price / Book
‪5.19‬
EV / EBITDA
‪-24.47‬
Profitability
Profit Margin
‪0.00%‬
Operating Margin
‪-8,079.10%‬
Return on Assets
‪-17.69%‬
Return on Equity
‪-26.06%‬
Ownership
Shares Outstanding
54.79M
Float
55.84M
Short % of Shares Outstanding
‪17.60%‬
Held by Insiders
‪0.12%‬
Held by Institutions
‪128.09%‬
Price stats
Beta
‪0.08‬
50-Day Avg
‪100.38‬
200-Day Avg
‪72.41‬
Dividends
Payout Ratio
‪0.00%‬
Analyst Consensus
14 analysts
Average price target
‪$ 137.62‬Shariah Compliance
Report Date: Feb 20, 2025
Screened by Zoya using the AAOIFI methodology.
Peers - DNTH - Dianthus Therapeutics Inc.
Peer Comparison
Compared with companies in Biotechnology listed on NASDAQ.
- DNTHNASDAQDianthus Therapeutics Inc.6.35BMarket Cap+79.20%52-week change3.30P/E (Trailing)‪0.00%‬Profit Margin
- ARGXNASDAQargenx SE American Depositary Receipt62.93BMarket Cap+33.08%52-week change39.69P/E (Trailing)‪32.26%‬Profit Margin
- ALNYNASDAQAlnylam Pharmaceuticals Inc31.58BMarket Cap-87.93%52-week change40.23P/E (Trailing)‪16.12%‬Profit Margin
- BNTXNASDAQBioNTech SE29.28BMarket Cap+9.87%52-week change160.80P/E (Trailing)‪-63.63%‬Profit Margin
- ASNDNASDAQAscendis Pharma A/S16.61BMarket Cap+23.98%52-week change19.38P/E (Trailing)‪70.84%‬Profit Margin
- BBIONASDAQBridgeBio Pharma, Inc.15.93BMarket Cap+41.98%52-week change-21.56P/E (Trailing)‪-97.02%‬Profit Margin
- BMRNNASDAQBiomarin Pharmaceutical Inc.12.91BMarket Cap+12.29%52-week change180.27P/E (Trailing)‪2.14%‬Profit Margin
Profile Summary - DNTH - Dianthus Therapeutics Inc.
About
Dianthus Therapeutics Inc. is a clinical-stage biotechnology company focused on developing next-generation complement therapeutics for patients with severe autoimmune and inflammatory diseases. It designs and delivers novel monoclonal antibodies and biologics with enhanced selectivity, potency, and dosing convenience…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Shariah compliance data provided by Zoya. Charting by TradingView.
Last updated:
